Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study.
Ghana
Ivermectin
Mass drug administration
Mixed-methods
Non-adherence
Onchocerciasis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Nov 2023
16 Nov 2023
Historique:
received:
26
02
2023
accepted:
08
11
2023
medline:
20
11
2023
pubmed:
17
11
2023
entrez:
17
11
2023
Statut:
epublish
Résumé
The World Health Organization has proposed that onchocerciasis elimination (interruption) of transmission be verified in 12 (approximately a third) endemic countries by 2030. The strategy to reach this goal is based on ivermectin Mass Drug Administration (MDA) with high geographical and therapeutic coverage. In addition to coverage, high levels of treatment adherence are paramount. We investigated factors associated with ivermectin intake in an area of Ghana with persistent Onchocerca volvulus infection. In August 2021, a cross-sectional mixed-methods study was conducted in 13 onchocerciasis-endemic communities in the Bono Region of Ghana. Individuals aged ≥ 10 years were invited to participate in a questionnaire survey. A total of 48 focus group discussions and in-depth interviews with 10 community drug distributors and 13 community leaders were conducted. A total of 510 people participated in the study [median age: 32, interquartile range 30 (20‒50) years]; 274 (53.7%) were females. Of the total, 320 (62.7%) declared that they adhered to each treatment round and 190 (37.3%) admitted they had not taken ivermectin during at least one MDA round, since becoming eligible for treatment. Of 483 participants with complete information, 139 (28.8%) did not take ivermectin during the last round (March 2021), and 24 (5.0%) had never taken ivermectin (systematic non-adherers). Reasons for not taking ivermectin included previous experience/fear of side-effects, being absent during MDA, pregnancy, the desire to drink alcohol, and drug distribution challenges. Being male, having good knowledge and perception of the disease, and not having secondary or higher level of formal education were significantly associated with higher odds of ivermectin intake. A relatively high level of non-adherence to ivermectin treatment was documented. There is a need for targeted educational and behavioural change campaigns to reverse these trends and ensure a steady course toward meeting onchocerciasis elimination targets in Ghana.
Sections du résumé
BACKGROUND
BACKGROUND
The World Health Organization has proposed that onchocerciasis elimination (interruption) of transmission be verified in 12 (approximately a third) endemic countries by 2030. The strategy to reach this goal is based on ivermectin Mass Drug Administration (MDA) with high geographical and therapeutic coverage. In addition to coverage, high levels of treatment adherence are paramount. We investigated factors associated with ivermectin intake in an area of Ghana with persistent Onchocerca volvulus infection.
METHODS
METHODS
In August 2021, a cross-sectional mixed-methods study was conducted in 13 onchocerciasis-endemic communities in the Bono Region of Ghana. Individuals aged ≥ 10 years were invited to participate in a questionnaire survey. A total of 48 focus group discussions and in-depth interviews with 10 community drug distributors and 13 community leaders were conducted.
RESULTS
RESULTS
A total of 510 people participated in the study [median age: 32, interquartile range 30 (20‒50) years]; 274 (53.7%) were females. Of the total, 320 (62.7%) declared that they adhered to each treatment round and 190 (37.3%) admitted they had not taken ivermectin during at least one MDA round, since becoming eligible for treatment. Of 483 participants with complete information, 139 (28.8%) did not take ivermectin during the last round (March 2021), and 24 (5.0%) had never taken ivermectin (systematic non-adherers). Reasons for not taking ivermectin included previous experience/fear of side-effects, being absent during MDA, pregnancy, the desire to drink alcohol, and drug distribution challenges. Being male, having good knowledge and perception of the disease, and not having secondary or higher level of formal education were significantly associated with higher odds of ivermectin intake.
CONCLUSIONS
CONCLUSIONS
A relatively high level of non-adherence to ivermectin treatment was documented. There is a need for targeted educational and behavioural change campaigns to reverse these trends and ensure a steady course toward meeting onchocerciasis elimination targets in Ghana.
Identifiants
pubmed: 37974087
doi: 10.1186/s12879-023-08806-8
pii: 10.1186/s12879-023-08806-8
pmc: PMC10655298
doi:
Substances chimiques
Ivermectin
70288-86-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
805Subventions
Organisme : United States Agency for International Development
ID : SGPIV/0111/241
Organisme : UK Medical Research Council and UK Foreign, Commonwealth & Development Office
ID : MR/R015600/1)
Informations de copyright
© 2023. The Author(s).
Références
Acta Leiden. 1990;59(1-2):9-24
pubmed: 2198761
PLoS Negl Trop Dis. 2016 Aug 16;10(8):e0004905
pubmed: 27529622
Trop Med Int Health. 2012 Jul;17(7):920-30
pubmed: 22575028
Infect Dis Poverty. 2023 Aug 17;12(1):75
pubmed: 37587500
PLoS Negl Trop Dis. 2012;6(9):e1825
pubmed: 23029586
BMJ Glob Health. 2021 Jan;6(1):
pubmed: 33431378
Clin Infect Dis. 2014 Oct;59(7):923-32
pubmed: 24944228
Clin Infect Dis. 2017 Nov 29;65(12):2026-2034
pubmed: 29020189
Lancet Glob Health. 2020 Jan;8(1):e92-e100
pubmed: 31839144
Philos Trans R Soc Lond B Biol Sci. 2023 Oct 9;378(1887):20220277
pubmed: 37598705
Parasite Epidemiol Control. 2021 Dec 23;16:e00235
pubmed: 35024476
BMC Infect Dis. 2023 Jul 10;23(1):460
pubmed: 37430222
Am J Trop Med Hyg. 2016 Nov 2;95(5):1037-1040
pubmed: 27352878
Parasit Vectors. 2015 Feb 15;8:99
pubmed: 25890151
PLoS Negl Trop Dis. 2017 Aug 14;11(8):e0005849
pubmed: 28806785
BMC Pharmacol Toxicol. 2019 Aug 16;20(1):49
pubmed: 31420005
Parasit Vectors. 2021 Jan 2;14(1):3
pubmed: 33388081
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Parasit Vectors. 2012 Feb 07;5:28
pubmed: 22313631
Parasit Vectors. 2016 Jan 27;9:29
pubmed: 26813098
BMC Res Notes. 2016 Apr 06;9:206
pubmed: 27053243
Trop Med Int Health. 2023 Nov;28(11):844-854
pubmed: 37846505
Int Health. 2018 Mar 1;10(suppl_1):i79-i88
pubmed: 29471335
J Infect Dis. 1995 Jul;172(1):204-10
pubmed: 7797912
Lancet Infect Dis. 2008 May;8(5):310-22
pubmed: 18471776
PLoS Negl Trop Dis. 2016 Jan 15;10(1):e0004328
pubmed: 26771545
Parasit Vectors. 2015 Dec 30;8:667
pubmed: 26715524
Pathogens. 2021 Dec 08;10(12):
pubmed: 34959543
Infect Dis Poverty. 2022 Jan 28;11(1):2
pubmed: 35086566
Parasit Vectors. 2011 Jul 27;4:152
pubmed: 21794139
Trop Med Int Health. 2005 Jul;10(7):659-67
pubmed: 15960704
Acta Trop. 2013 Aug;127(2):97-100
pubmed: 23583861
Parasit Vectors. 2018 Jun 19;11(1):356
pubmed: 29921312
Acta Trop. 2018 Sep;185:357-362
pubmed: 29932933
J Parasitol Res. 2021 Mar 29;2021:8866639
pubmed: 33859832